Drug-Drug Interaction Study of ABP-671 in Gout Patients

Condition(s) studied

Investigational drug(s) / intervention(s)

ABP-671 plus allopurinol: All subjects undergo three sequential 7-day periods: Period 1 (Day 1-7): Allopurinol； Period 2 (Day 1-7): Allopurinol Plus ABP-671； Period 3 (Day 1-7): ABP-671；

Study summary

This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.

Eligibility

Primary outcome measure(s)

• Maximum plasma concentration (Cmax) of allopurinol — Base line, through Day1, Day 7,Day8,D14,D15,D21
  Maximum observed plasma concentration (Cmax) of allopurinol following administration of allopurinol alone and in combination with ABP-671 at steady state.
• Area under the plasma concentration-time curve over the dosing interval (AUC) of allopurinol — Base line, through Day1, Day 7,Day8,D14,D15,D21
  Area under the plasma concentration-time curve over the dosing interval (AUC) of allopurinol following administration of allopurinol alone and in combination with ABP-671 at steady state.

Trial sites (1)